Showing results (81-90 of 135) with videos related to
Sort By:
Pageof 14
Pediatrics|January 9, 2020
Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured ChildrenKao-Ping Chua, Aaron L Schwartz, Anna Volerman, et al.The Milbank Quarterly|January 18, 2025
Innovative Insurance to Improve US Patient Access to Cell and Gene TherapyRena M Conti, Patrick Demartino, Jonathan Gruber, et al.Journal of Health Economics|May 23, 2002
The medical treatment of depression, 1991-1996: productive inefficiency, expected outcome variations, and price indexesErnst R Berndt, Anupa Bir, Susan H Busch, et al.The New England Journal of Medicine|February 15, 2002
Promotion of prescription drugs to consumersMeredith B Rosenthal, Ernst R Berndt, Julie M Donohue, et al.The American Economic Review|March 9, 2018
Quality Adjustment for Health Care Spending on Chronic Disease: Evidence from Diabetes Treatment, 1999–2009Karen N Eggleston, Nilay D Shah, Steven A Smith, et al.Gene Therapy|November 7, 2023
The estimated annual financial impact of gene therapy in the United StatesChi Heem Wong, Dexin Li, Nina Wang, et al.Journal of Health Politics, Policy and Law|July 22, 2022
Improving Access to High-Value, High-Cost Medicines: The Use of Subscription Models to Treat Hepatitis C Using Direct-Acting Antivirals in the United StatesSamantha G Auty, Kevin N Griffith, Paul R Shafer, et al.Pharmacoepidemiology and Drug Safety|August 4, 2010
Racial and ethnic disparities in cardiovascular medication use among older adults in the United StatesDima M Qato, Stacy Tessler Lindau, Rena M Conti, et al.Psychiatric Services (Washington, D.C.)|July 16, 2016
Patterns of Antipsychotic Prescribing by Physicians to Young ChildrenHaiden A Huskamp, Marcela Horvitz-Lennon, Ernst R Berndt, et al.Health Economics|October 3, 2006
Advance market commitments for vaccines against neglected diseases: estimating costs and effectivenessErnst R Berndt, Rachel Glennerster, Michael R Kremer, et al.Pageof 14